linjc16/ctgov huggingface dataset:
Kefir on Bone Mineral Density and Bone Metabolism in Osteoporotic Patients

Study Overview
=================
Brief Summary
-----------------
In a controlled, parallel, double-blind intervention study over 6 months, the investigators investigated the effects of kefir-fermented milk (1,600 mg/kg) supplemented with calcium bicarbonate (CaCO3, 1,500 mg/kg) and bone metabolism in 40 osteoporosis patients, and compared them with CaCO3 alone without kefir supplements. Bone turnover markers were measured in fasting blood samples collected before therapy and at 1, 3, and 6 months. BMD values at the spine, total hip, and hip femoral neck were assessed by dual-energy x-ray absorptiometry (DXA) at baseline and at 6 months.

Official Title
-----------------
Short-term Effect of Kefir-fermented Milk Consumption on Bone Mineral Density and Bone Metabolism in Osteoporotic Patients

Conditions
-----------------
Osteoporosis

Intervention / Treatment
-----------------
* Other: Placebo
* Other: CaCO3
* Other: Kefir


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of osteoporosis patients Exclusion Criteria: Any previous use of parathyroid hormone or sodium fluoride, use of anabolic steroids or growth hormone within 6 months before trial entry or oral or intravenous systemic corticosteroids within 12 months, and any previous use of strontium.

Ages Eligible for Study
-----------------
Minimum Age: 55 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Kefir and CaCO3<br>Kefir were administered 1,600 mg kefir-fermented milk per day and an accompanying supplement of 1,500 mg CaCO3 for 6 months | Other: Kefir<br>* Kefir daily for 6 months<br>|
| Placebo Comparator: Placebo and CaCO3<br>Placebo and 1,500 mg of CaCO3 daily for 6 months | Other: Placebo<br>* Placebo daily for 6 months<br>Other: CaCO3<br>* CaCO3 daily for 6 months<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| bone mineral density and bone regeneration |  | 3 months |
Ultrasound and Immunological Findings in Patients With Shoulder Injury Related to Vaccine Administration (SIRVA)

Study Overview
=================
Brief Summary
-----------------
Accidental vaccine injection into adjunct shoulder structures can cause tissue damage, termed Shoulder injury related to vaccine administration (SIRVA). The immunopathological mechanisms and consequences of SIRVA are unknown. The study assesses the clinical and immunological consequences of an influenza vaccine if accidentally administered in periarticular space.

Official Title
-----------------
Ultrasound and Immunological Findings in Patients With Shoulder Injury Related to Vaccine Administration (SIRVA)

Conditions
-----------------
Shoulder Injury Related to Vaccine Administration, Erosion, Localized

Intervention / Treatment
-----------------
* Diagnostic Test: Ultrasound Shoulder and Immunological Phenotyping by FACS


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: participation at a local vaccination campaign Shoulder pain >3 days after vaccination Exclusion Criteria: no vaccine received preexisting shoulder pathology

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| SIRVA<br>Subjects with shoulder pain >7 days after vaccination | Diagnostic Test: Ultrasound Shoulder and Immunological Phenotyping by FACS<br>* Cross-sectional Ultrasound exam of the affected shoulder. Peripheral blood measurements of the T and B cell subsets. Anti-Influenza Antibody measurements<br>|
| Controls<br>Subjects from a prospective influenza vaccine study | Diagnostic Test: Ultrasound Shoulder and Immunological Phenotyping by FACS<br>* Cross-sectional Ultrasound exam of the affected shoulder. Peripheral blood measurements of the T and B cell subsets. Anti-Influenza Antibody measurements<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pathological Findings in Ultrasound | Cross-sectional assessment and description of pathological ultrasound findings in subjects with shoulder pain after influenza vaccination | Ultrasound of the shoulder is performed at Baseline/Inclusion | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Increased Vaccine response | Antibodies against Influenza, Plasmablasts and T follicular helper cell increase | Baseline and 12 months |
Longitudinal Follow-up Study for Food Allergies

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the clinical usefulness of assessing specific human allergy antibodies and other immunologic parameters associated with the diagnosis, evolution, and management of allergic disease.

Detailed Description
-----------------
The purpose of this study is to strengthen our ability to understand the long-term effects of food immunotherapy on the immune system and how it may induce tolerance to foods that participants were once allergic to. Investigators hope to determine tools and immunologic parameters that can help predict sustained desensitization and tolerance to food allergens following food immunotherapy. By evaluating the in-depth characteristics of allergy antibody populations and other immunologic parameters and comparing them to clinical disease, the investigators may uncover a more sound way to diagnose, follow and treat food allergic disease over time. Investigators will follow up with participants who underwent immunotherapy to food allergens as volunteers in clinical trials at the Sean N. Parker Center and assess whether they experience sustained desensitization to these foods in the long-term. Investigators will investigate the properties of the participants' immune cells and how they are affected over time by the ingestion of these food allergens. Investigators will follow the significance of different dosing regimens in terms of achieving tolerance. Differences in immune cell characteristics and other biological parameters may help predict the nature of a participant's tolerance to the food allergens and may help in the development of tools to determine permanent tolerance.

Official Title
-----------------
Longitudinal Follow-up Study for Food Allergies

Conditions
-----------------
Food Allergy

Intervention / Treatment
-----------------
* Other: Immunotherapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients ages 6 months through 70 years who have previously undergone a food immunotherapy protocol only at our center. Exclusion Criteria: None. However, if a participant becomes pregnant, their clinic visit may be postponed until after delivery and/or lactation period. These subject can postpone visits for one year and choose to skip visits during pregnancy and another year after (if breastfeeding).

Ages Eligible for Study
-----------------
Minimum Age: 6 Months
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Immunotherapy|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Immunological markers | IgE, IgG4, T cells | February 2027 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
IgE, Allergy, Tolerance, Immunotherapy, Desensitization
Evening Primrose Oil to Misoprostol During Induction of Second-trimester Missed Miscarriage

Study Overview
=================
Brief Summary
-----------------
Termination of pregnancy is an important subject that has complex and emotional controversies. The most common time of termination of pregnancy is the mid-trimester which has two-thirds of all serious abortion-related complications. There are many indications for mid trimester termination of pregnancy such as missed abortion, serious fetal abnormalities and lastly some women do not wish to continue a pregnancy and will often request termination of pregnancy

Official Title
-----------------
The Effect of Adding Vaginal Evening Primrose Oil to Misoprostol During Induction of Second-trimester Missed Miscarriage; a Randomized Controlled Trial

Conditions
-----------------
Missed Abortion

Intervention / Treatment
-----------------
* Drug: Misoprostol 100Mcg Tab
* Drug: Evening Primrose Oil 1000 MG


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Nullipara or previous vaginal delivery only Bishop score was ≤ 5 Women who will accept to participate in the study Exclusion Criteria: Multiple gestations Rupture of fetal membranes Previous cesarean sections Women with heavy bleeding Evidence of low implanted placenta by US Evidence of intra-uterine infection (either clinical or laboratory)
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: study group<br>Misoprostol + Evening primrose oil group | Drug: Misoprostol 100Mcg Tab<br>* women will receive misoprostol 100 mcg (Misotac, Sigma Pharmaceuticals, Egypt) vaginally applied every 6 hours till cervical dilatation.<br>Drug: Evening Primrose Oil 1000 MG<br>* women will receive 4 capsules evening primrose oil 1000 mg (Primrose plus, Ema Pharm, Egypt) vaginally applied every 6 hours till cervical dilatation.<br>|
| Active Comparator: control group<br>Misoprostol only group | Drug: Misoprostol 100Mcg Tab<br>* women will receive misoprostol 100 mcg (Misotac, Sigma Pharmaceuticals, Egypt) vaginally applied every 6 hours till cervical dilatation.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The induction to fetal expulsion time. | Duration of delivery of fetus | 24 hours |
The Effect of Roux-en-Y Gastric Bypass on Bone Turnover

Study Overview
=================
Brief Summary
-----------------
Bone mineral density (BMD) is decreased after Roux-en-Y gastric bypass (RYGB) but whether RYGB induces changes in BMD beyond adaptation to major weight loss is not known. We aim to investigate BMD changes in weight bearing (hip, lumbal columna) and in non-weight bearing (forearm) regions before and after maximal weight loss at 1 year and after weight stabilisation at 4 years after RYGB. Moreover, plasma markers of bone turnover will be studied at fasting and during oral glucose tolerance test.

Official Title
-----------------
Bone Mineral Density and Markers of Bone Turnover After Roux-en-Y Gastric Bypass

Conditions
-----------------
Obesity, Gastric Bypass Surgery, Bone Loss

Intervention / Treatment
-----------------
* Procedure: Roux-en-Y gastric bypass


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participation in previos study ((NCT 01202526) Exclusion Criteria: Treatment of osteoporosis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| RYGB patients with preoperative type diabetes<br>Recruited from a previously investigated cohort (NCT 01202526) | Procedure: Roux-en-Y gastric bypass<br>* Roux-en-Y gastric bypass surgery for morbid obesity<br>|
| RYGB patients with preoperative normal glucose tolerance<br>Recruited from a previously investigated cohort (NCT 01202526) | Procedure: Roux-en-Y gastric bypass<br>* Roux-en-Y gastric bypass surgery for morbid obesity<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in bone mineral density of non-weight bearing bone | DXA scans of forearm | 1 year, 4 years | 
| Changes in bone mineral density of weightbearing bone | DXA scans of hip and lumbal columna | 1 year, 4 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Plasma markers of bone turnover | At fasting | 1 week, 3 months, 1 year, 4 years | 
| Plasma markers of bone turnover | during OGTT | 3 months, 1 year, 4 years |
Diet and Nutritional Status of Adolescent Girls in Zambézia, Mozambique

Study Overview
=================
Brief Summary
-----------------
Data on the diet and nutritional status of adolescent girls in Zambézia Province, Mozambique was collected. A cross-sectional study was carried out in 2010 in two seasons, January-February and May-June. Participants (total n=551) were recruited from Quelimane (the provincial capital), Maganja da Costa district and Morrumbala district.

Official Title
-----------------
Estudo do Estado Nutricional e da Dieta em Raparigas Adolescentes na Zambézia

Conditions
-----------------
Nutritional Status, Diet

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Girls in the target age range who were able to visit the study centre and didn't have any significant illness preventing participation were considered eligible. Exclusion Criteria:• age not between 15 and 18 years any apparent significant illness, disability or unstable medical condition which could lead to difficulty participating in the study unwillingness to participate in the study unwillingness or inability to arrive at the study location at the requested time.

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood vitamin and mineral concentrations |  | cross-sectional 2010, single measurement | 
| Dietary assessment | 24-hr recall, food frequency questionnaire | cross-sectional 2010, single measurement | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diseases (intestinal helminths, malaria parasitemia, HIV-status) |  | cross-sectional 2010, single measurement | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Adolescent girls, Mozambique, Diet, Anthropometrics, Serum biomarkers
Subcutaneous NTG for US Radial Artery Cannulation

Study Overview
=================
Brief Summary
-----------------
Clinicians are increasingly dealing with morbid obese patients. In morbid obese patients, difficult sampling and problems encountered with noninvasive blood pressure monitoring makes arterial cannulation an essential skill in many situations like surgeries or trans-radial procedures for coronary or carotid interventions. Radial artery has been preferred over other sites for arterial cannulation due to low incidence of bleeding, better hemostats, more comfort, and immediate ambulation. sm In this study, subcutaneous nitroglycerin will be used to facilitate radial artery cannulation aiming to decrease insertion time, increase success rate and decrease related complications

Conditions
-----------------
Morbid Obesity

Intervention / Treatment
-----------------
* Drug: Subcutaneous nitroglycrin
* Drug: Subcutaneous saline


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: morbid obese indicated for radial artery cannuulation Exclusion Criteria: +ve allen test peripheral arterial disease refusal

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Control group<br> | Drug: Subcutaneous saline<br>* In both groups, a 1 ml filled insulin syringe is delivered to a blinded operator who infiltrated it subcutaneously over 1 cm along the radial artery course. In the NTG group, the syringe contains 200 µg of NTG while in control group the syringe is filled with saline<br>|
| Active Comparator: NTG group<br> | Drug: Subcutaneous nitroglycrin<br>* In both groups, a 1 ml filled insulin syringe is delivered to a blinded operator who infiltrated it subcutaneously over 1 cm along the radial artery course. In the NTG group, the syringe contains 200 µg of NTG while in control group the syringe is filled with saline<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Success rate |  | 24 hours after surgery |
Microtransplantation With Decitabine and Cytarabine Improves Patient Outcomes in Myelodysplastic Syndromes

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate whether infusion of G-CSF mobilized HLA-mismatched peripheral blood stem cells (G-PBSC) combining decitabine and cytarabine chemotherapy can improve outcomes in myelodysplastic syndromes (MDS) patients.

Conditions
-----------------
Myelodysplastic Syndromes

Intervention / Treatment
-----------------
* Biological: Microtransplantation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients 10 to 90 years old with primary or treatment-related MDS or chronic myelomonocytic leukemia; International Prognostic Scoring System(IPSS) intermediate-1,intermediate-2,or high risk; bone marrow blasts > 11% or <= 10% and poor cytogenetics; lack of an HLA-identical donor; Eastern Cooperative Oncology Group (ECOG) performance status 0-2; adequate cardiac and hepatorenal functions. Exclusion Criteria: have an HLA-identical donor

Ages Eligible for Study
-----------------
Minimum Age: 10 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Decitabine and cytarabine<br>induction therapy：decitabine 25mg/m2 daily for 4 days with cytarabine 150 mg/m2 daily for 7 days consolidation：decitabine 25mg/m2 daily for 4 days with cytarabine 2g/m2 q12h for 3 days | Biological: Microtransplantation<br>* Infusion of G-CSF mobilized HLA-mismatched peripheral blood stem cells (G-PBSC)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| complete remission |  | six months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| disease-free survival |  | three years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Decitabine, microtransplantation, myelodysplastic syndromes, chemotherapy
The Study of Infection and Cell Inflammation in Peritoneal Dialysate

Study Overview
=================
Brief Summary
-----------------
A progressive decline of plasma triggering receptor expressed on myeloid cells-1 (TREM-1) concentration indicates a favorable clinical evolution during the recovery phase of sepsis. The expression of TREM-1 in dialysate of peritoneal dialysis patients was not yet documented. We will collect the dialysate of peritonitis in peritoenal dialysis patients and analyze the time serial change.

Detailed Description
-----------------
The triggering receptor expressed on myeloid cells-1 (TREM-1) is a member of the immunoglobulin superfamily, and its expression is upregulated on phagocytic cells in the presence of bacteria or fungi (1). Several experiments by Bouchon and colleagues showed that TREM-1 mediates the acute inflammatory response to microbial products. Human tissues infected with bacteria are infiltrated with neutrophils and macrophages that express high levels of TREM-1. Conversely, TREM-1 is only weakly expressed in samples from patients with noninfectious inflammatory disorders. In addition, TREM-1 is shed from the membrane of activated phagocytes and can be found in a soluble form in body fluids. The presence of a soluble form of TREM-1 in samples of bronchoalveolar lavage fluid from mechanically ventilated patients has been shown to be a good indicator of infectious pneumonia. During sepsis, a progressive decline of plasma sTREM-1 concentration indicates a favorable clinical evolution during the recovery phase of sepsis. In addition, baseline sTREM-1 level may prove useful in predicting outcome of septic patients. We will collect the dialysate of peritonitis in peritoneal dialysis patients and analyze the time serials change.

Conditions
-----------------
Peritonitis, Kidney Failure

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: peritoneal dialysis patients, dialysis period for more than 3 months. Exclusion Criteria: age younger than 18 years old, Pregnant or lactating women. (Pre-menopause women, capable of bearing children will undergo pregnancy test)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
peritonitis, peritoneal dialysis, dialysate